NasdaqGM - Delayed Quote USD
Fate Therapeutics, Inc. (FATE)
1.2750
-0.1250
(-8.93%)
At close: June 13 at 4:00:02 PM EDT
1.2600
-0.01
(-1.18%)
After hours: June 13 at 7:54:49 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 563,074 | 4 |
| Sales | 361,972 | 4 |
| Net Shares Purchased (Sold) | 201,102 | 8 |
| Total Insider Shares Held | 1.99M | -- |
| % Net Shares Purchased (Sold) | 11.20% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| BRESSI JEROME CHARLES Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 15, 2025 |
| TAHL CINDY R Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 15, 2025 |
| TAHL CINDY R Officer | Sale at price 1.55 per share. | Direct | 8,764 | Jan 10, 2025 |
| VALAMEHR BAHRAM Chief Executive Officer | Sale at price 1.54 per share. | Direct | 13,406 | Jan 10, 2025 |
| BRESSI JEROME CHARLES Officer | Sale at price 1.55 per share. | Direct | 9,269 | Jan 10, 2025 |
| REDMILE GROUP, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Sale at price 1.68 per share. | Indirect | 573,943 | Dec 20, 2024 |
| REDMILE GROUP, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.68 per share. | Indirect | 668,580 | Dec 20, 2024 |
| REDMILE GROUP, L.L.C. Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Dec 12, 2024 |
| XU YUAN Director | Sale at price 4.23 per share. | Direct | 2,678 | Aug 6, 2024 |
| VALAMEHR BAHRAM Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jul 29, 2024 |
| TAHL CINDY R General Counsel | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jul 29, 2024 |
| DULAC EDWARD J III Chief Financial Officer | Sale at price 7.77 per share. | Direct | 19,013 | Mar 4, 2024 |
| DULAC EDWARD J III Chief Financial Officer | Sale at price 5.00 per share. | Direct | 9,245 | Jan 29, 2024 |
| WOLCHKO JOHN SCOTT Chief Executive Officer | Sale at price 4.37 per share. | Direct | 62,889 | Jan 9, 2024 |
| TAHL CINDY R General Counsel | Sale at price 4.37 per share. | Direct | 47,519 | Jan 9, 2024 |
| VALAMEHR BAHRAM Officer | Sale at price 4.38 per share. | Direct | 49,367 | Jan 9, 2024 |
| DULAC EDWARD J III Chief Financial Officer | Sale at price 4.37 per share. | Direct | 30,712 | Jan 9, 2024 |
| DULAC EDWARD J III Chief Financial Officer | Sale at price 3.66 per share. | Direct | 18,966 | Jan 2, 2024 |
| REDMILE GROUP, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 3.72 per share. | Indirect | 166,024 | Dec 26, 2023 |
| DULAC EDWARD J III Chief Financial Officer | Sale at price 3.50 per share. | Direct | 5,548 | Dec 18, 2023 |
| TAHL CINDY R General Counsel | Sale at price 2.40 per share. | Direct | 58,471 | Nov 9, 2023 |
| DULAC EDWARD J III Chief Financial Officer | Sale at price 2.80 per share. | Direct | 13,210 | Aug 18, 2023 |
| XU YUAN Director | Sale at price 3.71 per share. | Direct | 2,345 | Aug 4, 2023 |
| DULAC EDWARD J III Chief Financial Officer | Sale at price 4.83 per share. | Direct | 25,029 | Jul 5, 2023 |
| POWL BRIAN T Officer | Sale at price 4.87 per share. | Direct | 18,769 | Jul 5, 2023 |
Related Tickers
ALLO Allogene Therapeutics, Inc.
1.3400
-4.29%
EDIT Editas Medicine, Inc.
1.9700
-9.63%
IOVA Iovance Biotherapeutics, Inc.
2.2400
-3.03%
CABA Cabaletta Bio, Inc.
1.9900
+10.56%
MGNX MacroGenics, Inc.
1.5200
-1.94%
BEAM Beam Therapeutics Inc.
17.06
-2.18%
SANA Sana Biotechnology, Inc.
2.5900
+1.97%
CADL Candel Therapeutics, Inc.
5.13
-4.29%
PRME Prime Medicine, Inc.
1.4600
0.00%
NTLA Intellia Therapeutics, Inc.
8.31
-0.48%